NEWSROOM

Wound Care

BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference

BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference

Feb 20, 2026

POMPANO BEACH, Fla., February 20, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today announced that Company management will present at the 46th Annual TD Cowen Healthcare Conference being held in Boston, MA. 46th Annual TD Cowen Healthcare Conference: Format: Presentation...

BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference

BioStem Technologies Highlights Alignment with FDA’s Openness to Bayesian Statistical Approaches in Clinical Research

Feb 3, 2026

POMPANO BEACH, Fla., February 3, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today underscored the significance of recent remarks from U.S. Food and Drug Administration (FDA) leadership signaling openness to expanded use of Bayesian statistical methodologies in clinical...

BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference

BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

Jan 7, 2026

Decision ensures continued patient access to VENDAJE® and VENDAJE AC® POMPANO BEACH, Fla., Jan. 07, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today commented on the withdrawal of all seven of the Centers for Medicare & Medicaid Services’ (“CMS”) Local Coverage...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

Dec 18, 2025

Status Quo designation preserves DFU/VLU reimbursement eligibility for 2026, ensuring continued patient access to BioStem technology Coverage for the majority of BioStem’s non-acute revenue, treatment for pressure ulcers, also remains unaffected by CMS LCD updates POMPANO BEACH, FL, December 18, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and...

BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference

BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference

Dec 10, 2025

Expanding its Portfolio with American Amnionto Serve the Wound Care Needs of Our Veterans BioStem Technologies launched two new placental-derived allografts—American Amnion and American Amnion AC—featuring its BioRetain processing technology. The products aim to enhance chronic wound healing with improved structural integrity and cell preservation, offering clinicians more consistent outcomes. The launch was showcased at the 2025 Desert Foot Conference, emphasizing support for veteran care...

BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference

BioStem Technologies Expands Product Access in Medicaid

Nov 25, 2025

Florida Medicaid Adds BioStem’s VENDAJEⓇ and VENDAJE ACⓇ to Covered Skin Substitutes List Key Takeaways Major reimbursement milestone — Florida Medicaid now covers VENDAJE® and VENDAJE AC®, expanding BioStem’s reach to 13 Medicaid programs nationwide. Significant market expansion — Florida, one of the largest Medicaid states, meaningfully grows BioStem’s addressable patient population and validates its clinical and economic value. Growth catalyst for 2026 — Expanded coverage strengthens...

BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference

BioStem Technologies Reports Third Quarter 2025 Financial Results

Nov 13, 2025

Key Takeaways Consistent Profitability — Q3 2025 net revenue reached $10.5M with $0.8M net income, marking BioStem’s seventh consecutive quarter of positive adjusted EBITDA. Clinical & Regulatory Progress — Positive BioREtain® trial results published in the International Journal of Tissue Repair; FDA reinspection completed with no observations. Strategic Expansion & Partnerships — BioStem secured land for its new Boca Raton HQ, partnered with a Service-Disabled Veteran-Owned Small...

BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference

BioStem Technologies Announces Filing of Restated Financial Statements

Nov 13, 2025

Key Takeaways Restated Financials Filed — BioStem filed restated interim and annual financial statements for 2023–2025, aligning with US GAAP for revenue recognition. Revenue Classification Update — Bona fide services fees from Venture Medical are now treated as contra revenue, lowering gross sales but not impacting EBITDA or cash flow. Audit and Uplist Progress — BioStem’s KPMG-led independent audit will conclude by Q1 2026, supporting plans to uplist and strengthen investor transparency....

BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference

BioStem Technologies Provides Comments on CMS CY 2026 Final Medicare Reimbursement Rule Changes for Skin Substitutes

Nov 5, 2025

Key Takeaways CMS’s final rule praised for transparency — BioStem welcomed the 2026 Medicare reimbursement reform for skin substitutes as a move toward a fair, predictable system rewarding proven outcomes. BioREtain® supports evidence-based care — The company’s BioREtain® allografts, validated in a Level 1 randomized trial showing superior outcomes, align with CMS’s push for clinically proven, cost-efficient products. Strong economics under new model — Vertically integrated GMP manufacturing...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies Secures Land Purchase at the Research Park at Florida Atlantic University in Boca Raton for Future Headquarters

Nov 5, 2025

Future Relocation and Expansion to Create Up to 100 New Jobs Over 5 Years City Approves Up to $300,000 in Economic Incentives to Rapidly Growing MedTech Business POMPANO BEACH, Fla., Nov. 5, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the purchase of land for...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers

Oct 31, 2025

Key Takeaways Superior healing with BioRetain® (BR-AC) — In the randomized trial, the probability of complete, lasting closure was 53% with BR-AC vs 31% with standard care, demonstrating a clear clinical benefit. Rigorous design focused on hard-to-heal DFUs — Multicenter RCT (11 U.S. sites) used a 2-week run-in; patients improving >30% on standard care were excluded. Closure had to remain sealed for 4 weeks to count as “lasting.” Clinical momentum and market need — BioStem is also enrolling...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025

Oct 30, 2025

Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., October 30, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announces it will release its third quarter 2025 financial results on Thursday, November 13, 2025, and will host a conference call and webcast...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant

Oct 27, 2025

POMPANO BEACH, FL, October 27, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM) (the “Company”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the Audit Committee of its Board of Directors has approved the appointment of KPMG LLP (“KPMG”) as the Company's independent registered public accounting firm, and it...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program

Oct 2, 2025

Program has honored more than 500 members of the military since its inception Sponsorship honors both local military veterans and healthcare professionals POMPANO BEACH, Fla., October 2, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, and the Florida Panthers, announced today that...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies (OTC: BSEM) Showcasing its Leading BioREtain®Technology at the Symposium for Advanced Wound Care (SAWC) Fall Meeting

Sep 5, 2025

Company co-exhibiting with strategic partner Venture Medical, LLC, highlighting collaborative innovation in chronic wound care management Three scientific posters feature BioStem’s proprietary allograft portfolio POMPANO BEACH, Fla., Sept. 05, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies to Present at Two Upcoming Investor Conferences

Sep 2, 2025

POMPANO BEACH, Fla., Sept. 02, 2025 - PRISM MediaWire - Press Release Service - Press Release Distribution - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced that Company management will present at the following upcoming investor conferences being held in New York, NY. Morgan Stanley Global Healthcare Conference: Format: Fireside Chat Date:...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies Announces Insider Share Purchase by Chairman and Chief Executive Officer

Aug 21, 2025

POMPANO BEACH, FL, August 21, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, discloses an insider purchase of common stock from Jason Matuszewski, Chairman and Chief Executive Officer of BioStem Technologies. Mr. Matuszewski purchased a total of 15,500 shares on August 19, 2025, totaling approximately $100,000. The purchases were...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results

Aug 14, 2025

POMPANO BEACH, FL, August 14, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today reported preliminary financial results for the second quarter ended June 30, 2025. Recent Business Highlights: Appointed Brandon Poe as Chief Financial Officer, a seasoned financial executive with experience across the...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies Appoints Brandon Poe as Chief Financial Officer

Aug 14, 2025

Seasoned healthcare CFO with senior experience in capital markets and financial operations across private and publicly traded companies to lead BioStem’s financial team POMPANO BEACH, FL, August 14, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the appointment of Brandon Poe as its Chief...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies to Host Second Quarter 2025 Financial Results Conference Call on August 14, 2025

Jul 30, 2025

Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., July 29, 2025 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived products for advanced wound care, announces it will release its second quarter 2025 financial results on Thursday, August 14, 2025, and host a conference call and webcast at 4:30 PM ET. The webcast will feature a review of second quarter...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes

Jul 17, 2025

The Company welcomes CMS’ efforts to reform skin substitute payment policy and will continue to engage with CMS and other stakeholders to optimize the proposed changes POMPANO BEACH, Fla., July 17, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, comments on the Centers for Medicare and Medicaid Services (“CMS”) release of the...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies Completes Enrollment in Clinical Trial Evaluating BioREtain® Amnion Chorion for Treatment of Diabetic Foot Ulcers

Jun 23, 2025

Head-to-head study comparing BioREtain®- processed Amnion Chorion (BR-AC) allograft to standard of care initiated in Q4 2024 to demonstrate healing superiority Topline results and full data analysis expected in Q4 2025 POMPANO BEACH, Fla., June 23, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

Ernst & Young LLP (EY US) Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award Winner

Jun 17, 2025

Award celebrates bold leaders shaping the future through the world’s most ground-breaking companies POMPANO BEACH, Fla., June 17, 2025 - PRISM MediaWire - Ernst & Young LLP (EY US) announced that Jason Matuszewski, CEO and Chairman of the Board of BioStem Technologies (OTC: BSEM), was named an Entrepreneur Of The Year 2025 Florida Award winner. Entrepreneur Of The Year is the preeminent competitive awards program for entrepreneurs and leaders of high-growth companies. For 40 years, EY US...

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 29, 2025

POMPANO BEACH, Fla., May 29, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that the company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami. Jason Matuszewski, the Company’s CEO, will participate in a fireside chat and will be available for...

BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference

Ernst & Young (EY) US Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award finalist

May 22, 2025

Entrepreneur Of The Year celebrates ambitious entrepreneurs who are shaping the future POMPANO BEACH, Fla., May 22, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (the “Company” or “BioStem”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that Jason Matuszewski, CEO of BioStem is an Ernst & Young LLP (EY US) finalist for the prestigious Entrepreneur...

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem to Showcase its Leading BioREtain® Technology at the Symposium for Advanced Wound Care (SAWC) Spring Meeting

May 1, 2025

Company to co-exhibit with strategic partner Venture Medical, LLC, highlighting collaborative innovation in chronic wound care management Three accepted scientific posters will feature BioStem’s advanced allograft portfolio POMPANO BEACH, Fla., May 1, 2025 - PRiSM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced its agenda for the...

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies to Host First Quarter 2025 Financial Results Conference Call on May 12, 2025

Apr 30, 2025

Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., April 30, 2025 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces it will release its first quarter 2025 financial results on Monday, May 12, 2025, and will host a conference call and webcast at 4:30 PM ET. The webcast will feature an overview of the...

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies to Present at the Centri Capital Conference

Apr 21, 2025

The presentation will be webcast at 10:30 AM ET on April 22, 2025 POMPANO BEACH, Fla., April 21, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, is pleased to announce that its Chief Executive Officer, Jason Matuszewski, will be presenting and holding one-on-one meetings at the upcoming Centri Capital...

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million

Apr 14, 2025

Company reports record preliminary fourth quarter net revenue of $102.9 Million, contributing to a total of $301.8 Million in revenue for 2024 Achieves preliminary GAAP net income of $15.5 million, or $0.94 per share, marking the fourth consecutive quarter of profitability Preliminary Q4 2024 Adjusted EBITDA of $11.1 Million Financial Results Conference Call and Webcast to be held on April 14, 2025 at 4:30 pm ET POMPANO BEACH, FL, April 14, 2025 - PRISM MediaWire - BioStem Technologies, Inc....

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on April 14, 2025

Apr 8, 2025

Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., April 08, 2025 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that it will release its fourth quarter and full year 2024 financial results on Monday, April 14, 2025, and host a conference call and webcast at 4:30 PM ET. The webcast will feature an overview...